In 2016, they only lost two matches all tournament. They boast the world’s top-ranking T20I batter, in Dawid Malan, in an order that packs plenty of punch with the likes of Jason Roy, Jos Buttler, and captain Morgan, alongside a well-rounded attack blessed with both pace and guile. The clash between the two sides pits two of the format’s most well-rounded and explosive teams against one another.Įoin Morgan’s team have only improved and evolved since then and quite rightly sit on top of the ICC T20I rankings. It was at the T20 World Cup 2016 that England announced themselves as a white ball force to be reckoned with, storming their way to the decider off the back of a power-packed batting order with a tail that didn’t start until No.10. That’s what a showstopping performance in a tournament final can do. Nevertheless, his name is now forever woven into the rich tapestry of the West Indies’ proud cricketing history and the T20 World Cup’s growing legend. In 2016, Carlos Brathwaite hit four consecutive sixes to seal the West Indies’ second Men’s T20 World Cup crown and we’ve remembered the name ever since.īarring a late call-up, Brathwaite won't play in this month's tournament. The world’s No.1 men’s T20I side and the reigning T20 World Cup champions meet again with memories of their last clash at the showpiece tournament still fresh. WEST INDIES VS ENGLAND - 23 October, Dubai Ten days out from the opening match, we take a look at 10 unmissable matches from the tournament. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.The ICC Men’s T20 World Cup 2021 is officially in eyesight. © 2014 by the American Diabetes Association. Events were mostly mild to moderate and transient.īoth once-weekly dulaglutide doses demonstrated superior glycemic control versus placebo and exenatide with an acceptable tolerability and safety profile. The most common gastrointestinal adverse events for dulaglutide were nausea, vomiting, and diarrhea. At 26 and 52 weeks, total hypoglycemia incidence was lower in patients receiving dulaglutide 1.5 mg than in those receiving exenatide no dulaglutide-treated patients reported severe hypoglycemia. Greater percentages of patients reached HbA1c targets with dulaglutide 1.5 mg and 0.75 mg than with placebo and exenatide (all P < 0.001). Both dulaglutide doses were superior to placebo at 26 weeks (both adjusted one-sided P < 0.001) and exenatide at 26 and 52 weeks (both adjusted one-sided P < 0.001). Mean baseline HbA1c was 8.1% (65 mmol/mol). Patients were treated with metformin (1,500-3,000 mg) and pioglitazone (30-45 mg). This 52-week, multicenter, parallel-arm study (primary end point: 26 weeks) randomized patients (2:2:2:1) to dulaglutide 1.5 mg, dulaglutide 0.75 mg, exenatide 10 μg, or placebo (placebo-controlled period: 26 weeks). The primary objective was to determine superiority of dulaglutide 1.5 mg versus placebo in HbA1c change at 26 weeks. To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients.